The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer.
Seil I, Frei C, Sültmann H, Knauer SK, Engels K, Jäger E, Zatloukal K, Pfreundschuh M, Knuth A, Tseng-Chen Y, Jungbluth AA, Stauber RH, Jäger D.
Seil I, et al. Among authors: jager d, jager e.
Int J Cancer. 2007 Jun 15;120(12):2635-42. doi: 10.1002/ijc.22620.
Int J Cancer. 2007.
PMID: 17330232